Hui Song1,2, Jue Yang3,4, Yongqiang Zhang5, Jianjiang Zhou1,2, Yanmei Li3,4, Xiaojiang Hao3,4. 1. The Key Laboratory of Endemic & Ethnic Diseases, Guizhou Medical University, Ministry of Education, Guiyang 550004, PR China. 2. The Key Laboratory of Medical Molecular Biology, Guizhou Medical University, Guizhou Province, Guiyang 550004, PR China. 3. The State Key Laboratory of Functions & Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, PR China. 4. The Key Laboratory of Chemistry for Natural Products of Guizhou Province & Chinese Academic of Sciences, Guiyang 550014, PR China. 5. School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, PR China.
Abstract
AIM: We aim to identify differentially expressed pseudogenes and investigate their functional roles in carcinogenesis. MATERIALS & METHODS: Here, we identify dysregulated pseudogenes, analyze their prognostic values and investigate their potential functions through pseudogene-miRNA-mRNA network from public -omics repositories. RESULTS: We identified 16 frequently upregulated pseudogenes among which high expression levels of RP11-564D11.3 was significantly associated with poor overall survival in seven types of human cancers. RP11-564D11.3 was strongly correlated with pathways in cancer, PI3K-Akt signaling pathway and the neurotrophin signaling pathway. Further studies revealed that RP11-564D11.3 functions as a competitive endogenous RNA through targeting VEGFA in hepatocellular carcinoma. CONCLUSION: Our findings suggest RP11-564D11.3 as a novel biomarker and therapeutic potential target against hepatocellular carcinoma.
AIM: We aim to identify differentially expressed pseudogenes and investigate their functional roles in carcinogenesis. MATERIALS & METHODS: Here, we identify dysregulated pseudogenes, analyze their prognostic values and investigate their potential functions through pseudogene-miRNA-mRNA network from public -omics repositories. RESULTS: We identified 16 frequently upregulated pseudogenes among which high expression levels of RP11-564D11.3 was significantly associated with poor overall survival in seven types of humancancers. RP11-564D11.3 was strongly correlated with pathways in cancer, PI3K-Akt signaling pathway and the neurotrophin signaling pathway. Further studies revealed that RP11-564D11.3 functions as a competitive endogenous RNA through targeting VEGFA in hepatocellular carcinoma. CONCLUSION: Our findings suggest RP11-564D11.3 as a novel biomarker and therapeutic potential target against hepatocellular carcinoma.
Authors: Lourdes Cruz-Garcia; Grainne O'Brien; Botond Sipos; Simon Mayes; Michael I Love; Daniel J Turner; Christophe Badie Journal: Radiat Res Date: 2019-12-12 Impact factor: 2.841